The Foundation

We are the largest nonprofit fighting poverty, disease, and inequity around the world. Founded on a simple premise: people everywhere, regardless of identity or circumstances, should have the chance to live healthy, productive lives. We believe our employees should reflect the rich diversity of the global populations we aim to serve.We provide an exceptional benefits package to employees and their families which include comprehensive medical, dental, and vision coverage with no premiums, generous paid time off, paid family leave, foundation-paid retirement contribution, regional holidays, and opportunities to engage in several employee communities.As a workplace, we’re committed to creating an environment for you to thrive both personally and professionally.

The Team

The FP&A team is responsible for partnering with program strategy teams (PST) and leadership to assess and optimize portfolios to achieve foundation goals, engaging with partners and grantees, and identifying and analyzing grants to maximize foundation impact.

Portfolio Management: Partner with program teams to optimize and allocate finite resources across portfolios to achieve foundation goals using a fluid capital market approach to fund priorities.

Partners and Grantees: Engage in coordinated strategic and business analysis across funders and institutions with shared strategic objectives and strengthen partners to improve their capacity to execute.

Grants: Partner with Program Officers to assess value for money, identify and mitigate risk, and provide financial analysis to the program team in order to maximize grant impact.

This role will be posted 10/9/2026 to 10/30/2026
This role is a 9-month Limited Term Employment (LTE) and is open in Seattle, WA, Washington, D.C. or Remote.

Your Role
The Finance Manager role is responsible for providing business, financial analysis and modeling support to the US Program Division, with an ideal candidate having a proven track record of working in a cross-cutting financial role providing support to multiple stakeholders or programs, experience within the Education Technology and/or Education sectors. This role will directly support our K-12 Teaching and Learning and Postsecondary Learning & Navigation program teams execute on their approved strategies. This candidate will partners with other FP&A team members to support the division on grantee financial assessment and business case analysis, complex grant structuring, including financial due diligence, as well as building and managing key relationships. Other responsibilities include budgeting and financial planning, resource allocation, and supporting other foundation-wide priorities.

What You'll Do

Provide support, financial analysis, and business advice to program teams and drive business case analyses in partnership with FP&A colleagues, program team members, and provide proactive feedback to program team members and potential partners related to factors such as grant structure, organizational effectiveness of the partners, business and pricing strategy and more.

Lead ad hoc complex analyses and provide program leadership with strategic and financial information to support budget management, forecasting and effective financial resource allocation and decision-making through the foundation’s financial and strategic processes.

Support annual budgeting and financial planning processes, including partnering with other FP&A team members, Program Officers and the Strategy, Planning and Management teams to translate business strategy into mid and long-range forecasts to produce detailed, dynamic 4-year budgets, as well as risk assessments and scenario modeling.

Proactively support organizational assessments/due diligence of key grantees/partners, and partner with Program Officers to develop appropriate mitigating strategies to manage financial and organizational risks of partners and grants.

Cultivate and manage key functional relationships and partnerships with internal stakeholders.

Lead forecast and portfolio allocation management for assigned PSTs, including the monitoring of actuals and forecasts to budget, with risk assessment and produce variance analysis.

Create dynamic financial planning tools that support decision-making and communication with program leadership.

Perform financial and risk analysis to support grant making and management.

Partner with programmatic teams to manage grant and contract spending.

Identify operational and financial risks of executing against annual budgets and broader planning horizons.

Assess business plans and perform financial sustainability analysis of organizations and specific projects. Advise program teams on risk mitigation actions including grants to strengthen the organizational capacity of partners.

Assess the financial and organizational health of grantee organizations through financial statements review and discussions with counter-level partners and other finance staff.

Drive data analyses to generate new insights on the grant portfolio, leading to improved allocation of resources.

Structure grants to optimize cash disbursements in consideration of operational risks.

Leverage tools and reports to plan and monitor workflow, forecast and payout performance.

Participate in cross-foundation efforts to develop tools and standard methodologies in support of effective grant-making, pipeline management and operational excellence.

Participate in complex transactions and special projects for teams with significant financial analysis component.

Other duties as assigned.

This position may require some travel, up to 10-15% of time

Your Experience

You are a creative, thoughtful, and curious professional who has an excellent track record of achievement in roles of increasing responsibility. You should be prepared to work across a diverse set of disciplines (e.g. business case analysis, forecasting, organizational capacity building, etc.), bridging a wide range of expertise, with a demonstrated ability to work with agility, and diplomacy in a dynamic environment. Additionally, we seek:

Bachelor’s degree with 7 years of financial planning experience, or equivalent years of relevant experience.

Experience in the technology, and educational technology and/or technology product development sector preferred.

Strong analytical acumen, especially financial modeling, and grant structuring.

Knowledge of risk management and organizational due diligence.

Robust analytical, quantitative, and modeling skills for a broad variety of transaction types.

Strong written and verbal communication skills that are appropriately right sized to relevant audiences.

Communicates sophisticated financial concepts to partners with a diverse set of backgrounds, including leadership, program staff, grantees, and other foundation operational resources.

Strong synthesizing skills and ability to absorb and quickly distill significant amounts of information.

Ability to read and analyze financial statements.

Strong project management skills and ability to work on multiple projects – or support multiple teams – simultaneously.

Strong relationship management skills with demonstrated success working with individuals at all levels of an organization.

Skilled in group problem-solving and teamwork to resolve problems involving internal and external partners.

Influences without formal authority and works with efficiency, diplomacy, and flexibility as part of a team with diverse cultural and professional backgrounds.

Highest level of integrity and leadership by example, helping to set the tone for the organization and demonstrate an affinity for creating and enabling an inclusive culture.

International finance experience/exposure preferred.

Advanced Excel skills and data visualization experience preferred.

Demonstrates intellectual curiosity.

Must have unrestricted work authorization in the country where this position is located. The Foundation does not provide immigration-related sponsorship for this role. This includes direct company sponsorship and any work authorization requiring a written submission or other immigration support from the company (eg: H-1B, O-1, L-1, E, OPT, STEM-OPT, CPT, TN, J-1, etc.).

The salary range for this role is $143,000 to $214,600 USD. We recognize high-wage market differences in Seattle and Washington D.C., where our offices are located. The range for this role in these locations is $130,000 to $195,000 USD. As a mission-driven organization, we strive to balance competitive pay with our mission. New hires salaries are typically between the range minimum and the salary range midpoint. Actual placement in the range will depend on a candidate’s job-related skills, experience, and expertise, as evaluated during the interview process.

#LK-AK1

Hiring Requirements

As part of our standard hiring process for new employees, employment will be contingent upon successful completion of a background check.

Candidate Accommodations

We’re committed to providing an inclusive and accessible hiring experience for all candidates. If you have a disability or medical condition and need an accommodation at any stage of the application or interview process—such as an ASL interpreter, alternative interview format, or physical accessibility support—we’re happy to help. Please contact [email protected] with the position number and a brief description of your accommodation needs. Requests will be handled confidentially.

Inclusion Statement

We are dedicated to the belief that all lives have equal value. We strive for a global and cultural workplace that supports ever greater diversity, equity, and inclusion — of voices, ideas, and approaches — and we support this diversity through all our employment practices.

All applicants and employees who are drawn to serve our mission will enjoy equality of opportunity and fair treatment without regard to race, color, age, religion, pregnancy, sex, sexual orientation, disability, gender identity, gender expression, national origin, genetic information, veteran status, marital status, and prior protected activity.

About the company

Gates Foundation is a philanthropic organization funding efforts to reduce poverty, disease, and inequity worldwide, working through grants to nonprofits, governments, and research institutions rather than delivering services directly. Its funding spans maternal and child health, infectious disease elimination including malaria, TB, HIV, and polio, smallholder farmer development, and women's economic empowerment, spread across thousands of active grants. What sets Gates Foundation apart is its selective, proactive grantmaking: staff invite organizations to submit proposals, run Grand Challenges competitions, and publish grant data and financials openly. The goal is to give every person, regardless of where they are born, the chance to live a healthy, productive life.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Seattle, Washington

Founded

2000

Get referred to Gates Foundation

See people who can refer or advise you

Simplify's Take

What believers are saying

Google and Gates committed $100 million for 200 million farmers on September 18, 2026.
MTN and Gates launched a $25 million Nigeria maternal health platform on September 22, 2026.
January 2026 budget expansion targets maternal health, polio eradication, and AI education.

What critics are saying

An Epstein review and staff cuts signal governance strain through 2030.
The foundation will eliminate up to 500 jobs, weakening execution capacity.
If AI pilots miss health outcomes by 2030, its credibility erodes fast.

What makes Gates Foundation unique

Bill Gates’ foundation plans a $9 billion annual payout through 2045.
It pairs massive grants with technical support, not donations alone.
It can broker governments, Google, MTN, and NGOs into deployment coalitions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Paid Time Off
Paid Family Leave
401(k) Retirement Plan
Remote Work Options
Hybrid Work Options
Flexible Work Hours
Wellness Program
Mental Health Support
Conferences Attendance Budget

Company News

Associated Press

Oct 23rd, 2026

Precisio Biotix wins Gates Foundation funding to develop engineered lysin treatment for BV

Precisio Biotix Therapeutics has received new funding from the Gates Foundation to advance a potential treatment for bacterial vaginosis (BV), one of the most common vaginal conditions among women worldwide. The company did not disclose the amount. BV occurs when harmful bacteria, particularly Gardnerella, displace beneficial ones. These bacteria form biofilms that shield them from antibiotics, and many are growing resistant to common drugs. Precisio develops engineered lysins, proteins designed to destroy specific harmful bacteria, including resistant ones and those within biofilms, while sparing beneficial bacteria. It builds them on its proprietary Zeus-LysiThru platform and aims for low-cost manufacturing to reach women in low- and middle-income countries. The funding will move promising candidates through preclinical development toward clinical testing. "Our goal is to break that cycle," said chief executive officer Mark Engel, referring to repeated antibiotic treatment and recurrence.

Business Insider

Oct 15th, 2026

Dalton Tx wins Gates Foundation grant to speed up AI-powered tuberculosis drug discovery

London-based Dalton Tx has won a grant from the Gates Foundation to speed up tuberculosis (TB) drug discovery with its AI platform, Dalton. The source did not disclose the grant amount. The funding will support large-scale computational screening of hundreds of essential and vulnerable genes in Mycobacterium tuberculosis, the bacterium that causes TB. Dalton combines protein structure prediction, machine learning and physics-based modelling to find new chemical starting points for drugs. The project will also test how well the models predict outcomes. Dalton Tx will partner with Ersilia, a non-profit that equips scientists in low- and middle-income countries with AI tools. Validated models, datasets and workflows will be available through the Ersilia Model Hub, alongside training and workshops across the Global South.

Newswire

Oct 14th, 2026

Continuity Biosciences awarded $9.6 million grant to advance ultra-long-acting implant for HIV prevention.

Continuity Biosciences awarded $9.6 million grant to advance ultra-long-acting implant for HIV prevention. Oct 14, 2026, 08:00 ET Funding supports development of a subcutaneous implant designed to deliver HIV prevention medicine for multiple years from a single placement, advancing toward an IND submission and initiation of a first-in-human Phase 1 study BRADENTON, Fla. and SEATTLE, Oct. 14, 2026 /CNW/ - Continuity Biosciences, LLC, a clinical-stage biotechnology company developing precision drug delivery platforms, today announced it has been awarded an up to $9.6 million grant from the Gates Foundation to advance a subcutaneous, ultra-long-acting antiretroviral (ARV) implant for HIV pre-exposure prophylaxis (PrEP) in low- and middle-income countries (LMICs). The implant is designed to deliver HIV prevention medicine continuously for multiple years after a single insertion under the skin. It is intended as an alternative to daily oral pills and to periodic injections, giving people at risk of HIV a prevention option that requires fewer dosing decisions and clinic visits. The grant will support development of Continuity's ultra-long-acting ARV implant through Investigational New Drug (IND)-enabling studies, submission of an IND application, and initiation of a Phase 1 first-in-human clinical study. "For many people, the challenge in HIV prevention is not the availability of effective medicines, but the burden of staying protected consistently over time," said Ramakrishna "Krishna" Venugopalan, PhD, MBA, Co-Founder and Chief Executive Officer of Continuity Biosciences. "A prevention option designed to provide protection for years could fundamentally change what is possible, particularly in communities where access to healthcare is limited. Despite major advances in prevention, there were 1.2 million new HIV infections in 2025, according to UNAIDS. Daily oral PrEP is highly effective when taken as prescribed, but sustaining adherence remains difficult for many people. Long-acting injectables have extended dosing intervals, yet still require regular clinic visits bi-monthly or bi-yearly currently, and a dependable supply chain. These challenges are even greater in low- and middle-income countries. Continuity's implant builds on the company's nanofluidic drug delivery technology, which uses precisely engineered channels to control drug release at a steady rate over an extended period. The approach is designed to sustain protective drug exposure over time while reducing the need for repeat dosing. "Our nanofluidic implant was engineered around a simple idea: HIV prevention shouldn't depend on remembering a daily pill or the next appointment," said Alessandro Grattoni, PhD, Co-Founder and Chief Scientific Advisor of Continuity Biosciences. "By controlling drug release at the device level, we aim to sustain constant ARV delivery for multiple years from a single implant. This support allows us to move that science from the laboratory toward a first-in-human evaluation." As part of the grant, Continuity has made Global Access commitments to the Gates Foundation, including making the resulting technology available at an affordable price to people most in need in low- and middle-income countries and broadly sharing knowledge gained from the program. Beyond HIV prevention, Continuity is applying its precision delivery platforms across type 1 diabetes, endocrinology, and oncology, including an ongoing first-in-human study of its iontophoretic oncology platform in pancreatic cancer. About Continuity Biosciences Continuity Biosciences is a clinical-stage biotechnology company developing precision drug delivery platforms for the controlled, sustained administration of therapeutics. Its technologies include intratumoral delivery systems for solid tumors, nanofluidic and subcutaneous long-acting implants, implantable devices for cell therapy, and microneedle systems for intradermal delivery. The company's programs span oncology, type 1 diabetes, endocrinology, HIV prevention, and medical aesthetics. For more information, visit www.continuitybiosciences.com. SOURCE Continuity Biosciences LLC Media Relations, Continuity Biosciences, [email protected]

PR Newswire

Oct 14th, 2026

Continuity Biosciences wins $9.6M Gates Foundation grant for multi-year HIV prevention implant

Continuity Biosciences, a clinical-stage biotechnology company based in Bradenton, Florida, and Seattle, has won a grant of up to $9.6 million from the Gates Foundation. The money will fund a subcutaneous implant that delivers HIV prevention medicine for multiple years from a single placement. The implant targets low- and middle-income countries. It aims to replace daily pills and regular injections, cutting the number of clinic visits needed. The grant covers studies required for an Investigational New Drug (IND) application, its submission, and the start of a first-in-human Phase 1 study. The implant uses nanofluidic technology to release the drug at a steady rate. In return, Continuity committed to making the technology affordable for people most in need and to sharing what it learns.

PR Newswire

Oct 14th, 2026

Continuity Biosciences awarded $9.6 million grant to advance ultra-long-acting implant for HIV prevention.

Continuity Biosciences awarded $9.6 million grant to advance ultra-long-acting implant for HIV prevention. 14 Oct, 2026, 12:00 GMT Funding supports development of a subcutaneous implant designed to deliver HIV prevention medicine for multiple years from a single placement, advancing toward an IND submission and initiation of a first-in-human Phase 1 study BRADENTON, Fla. and SEATTLE, Oct. 14, 2026 /PRNewswire/ - Continuity Biosciences, LLC, a clinical-stage biotechnology company developing precision drug delivery platforms, today announced it has been awarded an up to $9.6 million grant from the Gates Foundation to advance a subcutaneous, ultra-long-acting antiretroviral (ARV) implant for HIV pre-exposure prophylaxis (PrEP) in low- and middle-income countries (LMICs). The implant is designed to deliver HIV prevention medicine continuously for multiple years after a single insertion under the skin. It is intended as an alternative to daily oral pills and to periodic injections, giving people at risk of HIV a prevention option that requires fewer dosing decisions and clinic visits. The grant will support development of Continuity's ultra-long-acting ARV implant through Investigational New Drug (IND)-enabling studies, submission of an IND application, and initiation of a Phase 1 first-in-human clinical study. "For many people, the challenge in HIV prevention is not the availability of effective medicines, but the burden of staying protected consistently over time," said Ramakrishna "Krishna" Venugopalan, PhD, MBA, Co-Founder and Chief Executive Officer of Continuity Biosciences. "A prevention option designed to provide protection for years could fundamentally change what is possible, particularly in communities where access to healthcare is limited. Despite major advances in prevention, there were 1.2 million new HIV infections in 2025, according to UNAIDS. Daily oral PrEP is highly effective when taken as prescribed, but sustaining adherence remains difficult for many people. Long-acting injectables have extended dosing intervals, yet still require regular clinic visits bi-monthly or bi-yearly currently, and a dependable supply chain. These challenges are even greater in low- and middle-income countries. Continuity's implant builds on the company's nanofluidic drug delivery technology, which uses precisely engineered channels to control drug release at a steady rate over an extended period. The approach is designed to sustain protective drug exposure over time while reducing the need for repeat dosing. "Our nanofluidic implant was engineered around a simple idea: HIV prevention shouldn't depend on remembering a daily pill or the next appointment," said Alessandro Grattoni, PhD, Co-Founder and Chief Scientific Advisor of Continuity Biosciences. "By controlling drug release at the device level, we aim to sustain constant ARV delivery for multiple years from a single implant. This support allows us to move that science from the laboratory toward a first-in-human evaluation." As part of the grant, Continuity has made Global Access commitments to the Gates Foundation, including making the resulting technology available at an affordable price to people most in need in low- and middle-income countries and broadly sharing knowledge gained from the program. Beyond HIV prevention, Continuity is applying its precision delivery platforms across type 1 diabetes, endocrinology, and oncology, including an ongoing first-in-human study of its iontophoretic oncology platform in pancreatic cancer. About Continuity Biosciences Continuity Biosciences is a clinical-stage biotechnology company developing precision drug delivery platforms for the controlled, sustained administration of therapeutics. Its technologies include intratumoral delivery systems for solid tumors, nanofluidic and subcutaneous long-acting implants, implantable devices for cell therapy, and microneedle systems for intradermal delivery. The company's programs span oncology, type 1 diabetes, endocrinology, HIV prevention, and medical aesthetics. For more information, visit www.continuitybiosciences.com.

Gates Foundation

Finance Manager - Limited Term Employment

About the job

About the company

Get referred to Gates Foundation

Simplify's Take

What believers are saying

What critics are saying

What makes Gates Foundation unique

Benefits

Company News